OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

Fintel reports that on April 2, 2025, Lake Street initiated coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 865.16% Upside As of March 19, 2025, the ...

Shares of OSTX opened at $1.54 on Monday. The company’s fifty day moving average is $1.89 and its 200-day moving average is $2.73. OS Therapies has a 12 month low of $1.41 and a 12 month high of ...

Explore OS Therapies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OSTX. Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer ...

NEW YORK - OS Therapies (OSTX), a biopharmaceutical company specializing in clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) treatments, has announced progress with regulatory agencies ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy OS Therapies (NYSE-A: OSTX) (“OS Therapies” or ...

“2024 was a transformative year for OS Therapies as we completed our initial public offering and finalized the treatment phase of our Phase 2b clinical trial in the prevention of recurrence in ...